Fujifilm and Predictive Oncology Collaborate to Enhance Bacterial Endotoxin Detection in Biopharmaceuticals
RICHMOND, VA, and PITTSBURGH, April 25, 2024 - Fujifilm and Predictive Oncology Inc. (NASDAQ: POAI) have announced their collaboration and co-marketing agreement aimed at reducing protein interference in bacterial endotoxin testing of biopharmaceutical products. This partnership seeks to enhance the accuracy of detecting residual endotoxins in biopharmaceuticals by eliminating protein interference from the drug product in the detection assay.
Fujifilm, a renowned supplier of high purity chemicals and reagents, brings its PYROSTAR bacterial endotoxin detection reagent to the collaboration. This reagent has proven to be effective in detecting bacterial endotoxins that may contaminate biopharmaceutical products. Predictive Oncology, a leader in AI-driven drug discovery and biologics, will introduce its innovative EndoPrep sample treatment technology for this purpose.
Bacterial endotoxins, also known as lipopolysaccharides, are potent toxins produced by certain strains of bacteria. They are a common contaminant in biopharmaceutical products and can cause severe toxicity and adverse effects in patients if not detected and removed. Therefore, accurate detection of bacterial endotoxins is vital for ensuring the safety and efficacy of biopharmaceutical products.
However, one of the challenges in detecting residual endotoxins lies in the interference caused by the presence of proteins from the drug product itself. This interference can affect the sensitivity and accuracy of the detection assay, leading to false results. The collaboration between Fujifilm and Predictive Oncology aims to address this issue by developing a solution that can effectively eliminate protein interference.
Predictive Oncology’s EndoPrep sample treatment technology is designed to remove proteins from the drug product before the bacterial endotoxin detection assay. By effectively eliminating protein interference, the accuracy and reliability of the assay are expected to significantly improve.
Combining EndoPrep with Fujifilm’s PYROSTAR bacterial endotoxin detection reagent creates a comprehensive solution for enhancing the detection of residual endotoxins in biopharmaceutical products. The use of PYROSTAR, known for its high sensitivity and specificity, along with EndoPrep’s ability to eliminate protein interference, offers a promising approach to ensure the safety and quality of biopharmaceuticals.
This collaboration and co-marketing agreement between Fujifilm and Predictive Oncology not only holds great potential for the biopharmaceutical industry but also showcases the power of partnerships in advancing scientific innovation. Together, they aim to provide the pharmaceutical industry with a more accurate and reliable method for detecting bacterial endotoxins in biopharmaceutical products.
In conclusion, the collaboration between Fujifilm and Predictive Oncology brings together their expertise, resources, and technologies to address the challenge of protein interference in bacterial endotoxin detection testing. By combining Fujifilm’s PYROSTAR reagent and Predictive Oncology’s EndoPrep technology, the goal is to enhance the accuracy and reliability of detecting residual endotoxins in biopharmaceuticals, ultimately ensuring the safety and effectiveness of these products.
Comments